XRD-0610

XRD-0610 is an orally bioavailable, potent, and highly selective reversible (non-covalent) inhibitor of Bruton's tyrosine kinase (BTK) developed by X-Rx Biomedical. Unlike first-generation covalent BTK inhibitors such as ibrutinib, XRD-0610 does not require binding to the Cys481 residue, making it potentially effective against B-cell malignancies that have developed resistance via the C481S mutation. By inhibiting BTK, the drug disrupts B-cell receptor (BCR) signaling, which is critical for the proliferation and survival of malignant B cells. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin lymphoma.